000			01755 a2200493 4500
005			20250514053237.0
264		0	_c20030731
008			200307s 0 0 eng d
022			_a0268-3369
024	7		_a10.1038/sj.bmt.1703740 _2doi
040			_aNLM _beng _cNLM
100	1		_aNelson, R P
245	0	0	_aNonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma. _h[electronic resource]
260			_bBone marrow transplantation _cDec 2002
300			_a805-12 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCarcinoma, Renal Cell _ximmunology
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aCyclophosphamide
650	0	4	_aCytokines _xtherapeutic use
650	0	4	_aGraft Survival
650	0	4	_aGraft vs Host Disease _xetiology
650	0	4	_aGraft vs Tumor Effect
650	0	4	_aHumans
650	0	4	_aImmunotherapy, Adoptive
650	0	4	_aKidney Neoplasms _ximmunology
650	0	4	_aMelphalan
650	0	4	_aMulticenter Studies as Topic
650	0	4	_aNephrectomy
650	0	4	_aPeripheral Blood Stem Cell Transplantation _xadverse effects
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aSurvival Analysis
650	0	4	_aThiotepa
650	0	4	_aTransplantation Chimera
650	0	4	_aTransplantation Conditioning _xmethods
650	0	4	_aTreatment Outcome
650	0	4	_aVidarabine _xanalogs & derivatives
700	1		_aLogan, T F
700	1		_aAbonour, R
773	0		_tBone marrow transplantation _gvol. 30 _gno. 12 _gp. 805-12
856	4	0	_uhttps://doi.org/10.1038/sj.bmt.1703740 _zAvailable from publisher's website
999			_c12281038 _d12281038